KRAS and familial pancreatic carcinoma: The current work presented here applies a structured approach to screen for potential therapeutic synergisms of direct KRAS inhibition by means of three different compounds, AMG510, BI-3406, or BI-2852, respectively, with concomitant MEK inhibition using Binimetinib and radiation therapy in pancreatic cancer cells with different KRAS status.